Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products
Executive Summary
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies
You may also be interested in...
Amgen To Study Aranesp Anemia Indication In Heart Failure Patients
Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure
Amgen To Study Aranesp Anemia Indication In Heart Failure Patients
Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure
Amgen Kepivance To Launch In January; Additional Mucositis Trials Underway
Amgen will launch the oral mucositis treatment Kepivance (palifermin) in late January following FDA approval Dec. 15